231 related articles for article (PubMed ID: 27303300)
1. PACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR Expression.
Maugeri G; D'Amico AG; Reitano R; Magro G; Cavallaro S; Salomone S; D'Agata V
Front Pharmacol; 2016; 7():139. PubMed ID: 27303300
[TBL] [Abstract][Full Text] [Related]
2. Modulatory role of PACAP and VIP on HIFs expression in lung adenocarcinoma.
D'Amico AG; Maugeri G; Rasà DM; Reitano R; Saccone S; Federico C; Magro G; D'Agata V
Peptides; 2021 Dec; 146():170672. PubMed ID: 34627957
[TBL] [Abstract][Full Text] [Related]
3. Neuropeptides of the VIP family inhibit glioblastoma cell invasion.
Cochaud S; Meunier AC; Monvoisin A; Bensalma S; Muller JM; Chadéneau C
J Neurooncol; 2015 Mar; 122(1):63-73. PubMed ID: 25563813
[TBL] [Abstract][Full Text] [Related]
4. PACAP and VIP regulate hypoxia-inducible factors in neuroblastoma cells exposed to hypoxia.
Maugeri G; D'Amico AG; Rasà DM; Saccone S; Federico C; Cavallaro S; D'Agata V
Neuropeptides; 2018 Jun; 69():84-91. PubMed ID: 29699729
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
Delgado M; Ganea D
J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
[TBL] [Abstract][Full Text] [Related]
6. PKA at a Cross-Road of Signaling Pathways Involved in the Regulation of Glioblastoma Migration and Invasion by the Neuropeptides VIP and PACAP.
Bensalma S; Turpault S; Balandre AC; De Boisvilliers M; Gaillard A; Chadéneau C; Muller JM
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669581
[TBL] [Abstract][Full Text] [Related]
7. PACAP and VIP increase the expression of myelin-related proteins in rat schwannoma cells: involvement of PAC1/VPAC2 receptor-mediated activation of PI3K/Akt signaling pathways.
Castorina A; Scuderi S; D'Amico AG; Drago F; D'Agata V
Exp Cell Res; 2014 Mar; 322(1):108-21. PubMed ID: 24246222
[TBL] [Abstract][Full Text] [Related]
8. PACAP and VIP Inhibit HIF-1α-Mediated VEGF Expression in a Model of Diabetic Macular Edema.
Maugeri G; D'Amico AG; Saccone S; Federico C; Cavallaro S; D'Agata V
J Cell Physiol; 2017 May; 232(5):1209-1215. PubMed ID: 27661459
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
[TBL] [Abstract][Full Text] [Related]
11. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
13. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
Delgado M; Ganea D
J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
16. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
18. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology.
Wei Y; Mojsov S
J Neuroendocrinol; 1996 Nov; 8(11):811-7. PubMed ID: 8933357
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
20. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor.
Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M
Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
